Skip to main content
Computational and Mathematical Methods in Medicine logoLink to Computational and Mathematical Methods in Medicine
. 2018 Aug 29;2018:2434560. doi: 10.1155/2018/2434560

Mathematical Analysis of Influenza A Dynamics in the Emergence of Drug Resistance

Caroline W Kanyiri 1,, Kimathi Mark 2, Livingstone Luboobi 3
PMCID: PMC6136569  PMID: 30245737

Abstract

Every year, influenza causes high morbidity and mortality especially among the immunocompromised persons worldwide. The emergence of drug resistance has been a major challenge in curbing the spread of influenza. In this paper, a mathematical model is formulated and used to analyze the transmission dynamics of influenza A virus having incorporated the aspect of drug resistance. The qualitative analysis of the model is given in terms of the control reproduction number, Rc. The model equilibria are computed and stability analysis carried out. The model is found to exhibit backward bifurcation prompting the need to lower Rc to a critical value Rc for effective disease control. Sensitivity analysis results reveal that vaccine efficacy is the parameter with the most control over the spread of influenza. Numerical simulations reveal that despite vaccination reducing the reproduction number below unity, influenza still persists in the population. Hence, it is essential, in addition to vaccination, to apply other strategies to curb the spread of influenza.

1. Introduction

Influenza is a contagious respiratory illness caused by influenza viruses. There are three major types of flu viruses: types A, B, and C. The majority of human infections are caused by types A and B. Of major concern is influenza A virus which is clinically the most vicious. It is a negative-sense single-stranded RNA virus with eight gene segments. The segmented nature of influenza A virus genome allows the exchange of gene segments between viruses that coinfect the same cell [1]. This process of genetic exchange is termed reassortment. Reassortment leads to sudden changes in viral genetics and to susceptibility in hosts. Influenza A virus has a wide range of susceptible avian hosts and mammalian hosts such as humans, pigs, horses, seals, and mink. In addition, the virus is able to repeatedly switch hosts to infect multiple avian and mammalian species. The unpredictability of influenza A virus evolution and interspecies movement creates continual public health challenges [2].

Influenza A virus constantly mutates and is able to elude the immune system of an individual. It can mutate in two different ways: antigenic shift and antigenic drift. Antigenic shift is an abrupt, major change in the influenza virus which happens occasionally and results in a new subtype that most people have no protection against. Such a shift occurred in the spring of 2009 in Mexico and United States, when H1N1 virus with a new combination of genes emerged to infect people and quickly spread, causing a pandemic [3]. This antigenic shift was as a result of extensive reassortment in swine that brought together genes from avian, swine, and human flu viruses [4]. On the other hand, antigenic drift refers to small changes in the genes of influenza viruses that occur continually as the virus replicates. Over time, these small genetic changes result in new strains which the antibodies can no longer recognize. The changes in the influenza viruses are the main reason why individuals are infected with the flu more than once. The viruses infect the nose, throat, and lungs. They usually are spread through the air when the infected people cough, sneeze, or talk making the surrounding air and surfaces to be temporarily contaminated with infected droplets [5, 6]. People get infected when they inhale the infected droplets. A person might also get flu by touching the surface or object that has flu virus on it and then touching their own mouth, eyes, or possibly their nose [6].

Influenza can be prevented by getting vaccination each year. However, given that the virus mutates rapidly, a vaccine made for one year may not be useful in the following year. In addition, antigenic drift in the virus may occur after the year's vaccine has been formulated, rendering the vaccine less protective, and hence, outbreaks can easily occur especially among high-risk individuals [7]. According to [8], other preventive actions include staying away from people who are sick, covering coughs and sneezes, and frequent handwashing.

Influenza spreads rapidly around the world during seasonal epidemics and pandemics [9]. It has afflicted the human population for centuries. For instance, the 1918 influenza pandemic infected nearly one quarter of the world's population and resulted in the deaths of about 100 million people [10]. Studies show that this pandemic is especially responsible for the high morbidity and mortality among vulnerable groups such as children, the elderly, and patients with underlying health conditions [11]. Within the past one hundred years, there have been four pandemics resulting from the emergence of a novel influenza strain for which the human population possessed little or no immunity. Table 1 gives a brief summary of the four influenza pandemics.

Table 1.

Summary of influenza pandemics in the past one hundred years.

Pandemic name Year Strain Approximate number of deaths
Spanish flu 1918–1920 H1N1 40–100 million
Asian flu 1957–1958 H2N2 1–2 million
Hong Kong flu 1968–1970 H3N2 0.5–2 million
Swine flu 2009–2010 H1N1 Up to 575,000

Source: [10, 12, 13].

Besides the influenza pandemics, there is an outbreak of influenza every year around the world which results in about three to five million cases of severe illness and about 250,000 to 500,000 deaths [14]. According to a report by Centers for Disease Control and Prevention (CDC), as of December 2017, the estimated number of deaths worldwide resulting from seasonal influenza had risen to between 291,000 and 646,000 [15]. This new estimate was from a collaborative study by CDC and global health partners. In the temperate northern hemisphere (i.e., north of the Tropic of Cancer) and temperate southern hemisphere (i.e., south of the Tropic of Capricorn), influenza has been observed to peak in the winter months [16, 17]. In tropical regions, influenza seasonality is less obvious and epidemics can occur throughout the year and more specifically during the rainy seasons [18]. According to [19], the mortality rates due to this respiratory disease are much higher in Africa than anywhere else in the world. Poor nutritional status, poor access to healthcare including vaccination and antibiotics, and the presence of other, less measurable factors related to poverty in Africa may be additional risk factors for higher mortality rates. WHO Global Influenza Surveillance and Response System (GISRS) monitors the evolution of influenza viruses. Figures 1 and 2 show the global circulation of influenza viruses from 2016 to week 24 of 2018 [20, 21].

Figure 1.

Figure 1

Global circulation of influenza viruses from 2016 to 2017.

Figure 2.

Figure 2

Global circulation of influenza viruses from 2017 to week 24 of 2018.

Influenza-attributable mortality varies across the seasons. There is however paucity of published estimates of influenza mortality for low- and middle-income countries. Data from Centers for Disease Control and Prevention (CDC) databases from the 1999–2000 to the 2014–2015 seasons for the U.S. population aged 65 years and above were used to estimate excess deaths per month over that 15-year span [22]. The data are presented in Figure 3.

Figure 3.

Figure 3

Excess mortality due to influenza for the U.S. population aged 65 years and above.

In addition to pandemics and seasonal epidemics caused by influenza A virus, over the past 20 years, multiple zoonotic influenza A virus outbreaks have occurred causing a great concern to public health [2326]. For instance, H5N1 influenza virus from avian hosts poses an ongoing threat to human and animal health due to its high mortality rate [2628]. H7N9 is yet another highly pathogenic subtype of influenza A virus that is of major concern. According to the World Health Organization (WHO), as of January 2018, 1566 laboratory-confirmed cases of human infection with H7N9 virus have been reported in China, including at least 613 deaths [29]. In addition to the ongoing H5N1 and H7N9 influenza A virus outbreaks, other subtypes, such as H5N6, H9N2, H10N8, and H6N1, have sporadically caused serious human infections in China and Taiwan [3033]. The death toll from influenza is unacceptably high, given that it is preventable. Efforts to combat it must therefore be accelerated. In view of the catastrophic effects of influenza globally, several models have been proposed and analyzed with the aim of shedding more light in the transmission dynamics of influenza, for instance [3441]. Among the pioneer mathematical models used to describe influenza dynamics is one developed by [38].

Emergence of drug resistance which is a growing menace globally [42] complicates influenza even more [43, 44]. Drug resistance refers to reduction in the effectiveness of a drug in curing a disease. It occurs when microorganisms such as bacteria, viruses, fungi, and parasites change in ways that render the medications used to cure the infections they cause ineffective [45, 46]. The microorganisms are therefore able to survive the treatment. According to [47], epidemics with drug-resistant strains and those with drug-sensitive strains are fundamentally different in their growth and dynamics. Drug-sensitive epidemics are fuelled by only one process, that is, transmission; however, drug-resistant epidemics are fuelled by two processes: transmission and the conversion of treated drug-sensitive infections to drug-resistant infections (acquired resistance). Therefore, the rate of increase in drug-resistant infections can be much faster than the rate of increase in drug-sensitive infections. Studies from [48] show that drug resistance is a function of time and treatment rate. In addition, immunosuppression especially in individuals with compromised immune systems contributes to lack of viral clearance often despite antiviral therapy leading to emergence of antiviral resistance [49].

There are two classes of antiviral drugs that are used to treat influenza: adamantanes and neuraminidase inhibitors. The adamantanes are only effective against influenza A viruses, as they inhibit the M2 protein, which is not coded by influenza B [50]. These drugs are associated with several toxic effects and rapid emergence of drug-resistant strains. The neuraminidase inhibitors interfere with the release of progeny influenza virus from infected host cells, a process that prevents infection of new host cells and thereby halts the spread of infection in the respiratory tract [7]. Since these drugs act at the stage of viral replication, they must be administered as early as possible. According to [51], influenza viruses mutate constantly, either from one season to the next or within the course of one flu season. As a flu virus replicates, the genetic makeup may change rendering the virus resistant to one or more of the antiviral drugs used to treat or prevent influenza. Antiviral resistance in influenza may not only emerge during treatment but also sometimes transmit widely to replace wild-type strains in the absence of drug pressure. The transmission of resistant strains is evidenced by the global spread of adamantane-resistant A(H3N2) viruses since 2003, oseltamivir-resistant seasonal A(H1N1) viruses since 2007, and adamantane-resistant pandemic A(H1N1) viruses in 2009, leading to increased challenges in the management of influenza [52]. With the development of drug-resistant influenza viruses, various models have also been formulated in order to understand this phenomenon better. Among them are [5357].

The morbidity, mortality, and economic burden of influenza cannot be overlooked. With the emerging menace of drug resistance, this burden becomes even more complicated. In order to curb the spread of influenza, there is a dire need to understand among its many aspects, its transmission dynamics especially in light of the drug resistance aspect. In this paper, a mathematical model that illustrates the transmission dynamics of a wild-type influenza strain and the development and transmission of drug-resistant influenza strain is formulated and analyzed.

2. Mathematical Model

2.1. Model Formulation

The model subdivides the total population into five compartments: Susceptible (S), Vaccinated (V), Infected with Wild-type strain (Iw), Infected with Resistant strain (IR), and Recovered (R). Individuals in a given compartment are assumed to have similar characteristics. Parameters vary from compartment to compartment but are identical for all individuals in a given compartment. Individuals enter the population at the rate of π, and all recruited individuals are assumed to be susceptible. The Susceptible get infected after effective contact with either the Infected with Wild-type strain or the Infected with Resistant strain. The force of infection is given by either λ1=βwIw (Infection by Wild-type strain) or λ2=βr¯IR (Infection by Resistant strain), where βr¯=fβr,b. Parameters βw and βr refer to the transmission rate of wild-type strain and resistant strain, respectively. Parameter b is the rate of developing drug resistance. The susceptible can only be infected by one strain at a time. The rate of vaccination is ϕ. The vaccinated can also become infected with either the wild-type strain or the resistant strain. This depends on the vaccine efficacy. When the vaccine efficacy is 100%, the vaccinated cannot become infected. Individuals who are infected with the wild-type strain are treated and recover at the rate of α, while those who are infected with the resistant strain recover at the rate of αr. The wild-type strain is assumed to mutate to resistant strain, and hence, those infected with the wild type join those infected with the resistant strain at the rate of b. Individuals with wild-type strain and those with resistant strain suffer disease-induced death at the rates aw and ar, respectively. The recovered lose immunity at the rate of ϑ joins the susceptible class. Individuals in all the epidemiological compartments suffer natural death at the rate of μ. The model diagram is given in Figure 4.

Figure 4.

Figure 4

Schematic diagram showing population flow between different epidemiological classes.

2.2. Model Equations

Given the dynamics described in Figure 4, the following system of nonlinear ordinary differential equations, with nonnegative initial conditions, describes the dynamics of influenza:

dSdt=π+ϑRϕ+μ+λ1+λ2St,dVdt=ϕSt1ελ1+1ελ2+μVt,dIwdt=λ1St+1ελ1Vtb+μ+aw+αIwt,dIRdt=λ2St+1ελ2Vt+bIwtμ+αr+arIRt,dRdt=αIwt+αrIRtϑ+μRt, (1)

where λ1=βwIw and λ2=βr(1+b2)IR.

We assume that all the model parameters are positive and the initial conditions of the model system (1) are given by

S0>0,V00,IW00,IR00,R00. (2)

Table 2 gives the description of the various parameters used in the model along with reasonable estimates of their values.

Table 2.

Description and values of parameters used.

Parameter Description Value Reference
β w Transmission rate of wild-type strain 0.00102 day−1 Estimated
β r Transmission rate of resistant strain 0.00026 day−1 Estimated
ε Vaccine efficacy 0.77 [58]
ϕ Vaccination rate 0.00027375 day−1 [59]
b Rate of developing drug resistance 0.118 Estimated
α Recovery rate for individuals in Iw class 0.1998 day−1 [6]
α r Recovery rate for individuals in IR class 0.0714 day−1 Estimated
ϑ Rate of losing immunity 0.00833 day−1 [34]
a w Death rate due to infection with wild-type strain 0.01 [39]
1μ Average human lifespan 70 × 365 days Estimated
π Recruitment rate 0.0381 Estimated
a r Death rate due to infection with resistant strain 0.021 Estimated

3. Model Analysis

3.1. Basic Properties

3.1.1. Positivity of Solutions

The model system (1) monitors the changes in human population. It is therefore important to prove that the solutions of system (1) with nonnegative initial conditions will remain nonnegative for all t > 0. Thus, we have the following theorem:

Theorem 1 . —

Given that the initial conditions of system (1) areS(0) > 0, V(0) ≥ 0, IW(0) ≥ 0, IR(0) ≥ 0, and  R(0) ≥ 0, the solutionsS(t), V(t), Iw(t), IR(t), and  R(t)are nonnegative for allt > 0.

Proof —

Assume that

t^=supt>0:St>0,Vt>0,Iwt>0,IRt>0,Rt>00,t. (3)

Thus t^>0, and it follows directly from the first equation of system (1) that

dSdtπλ1+λ2+μS. (4)

Using the integrating factor method to solve inequality (4), we have

ddtStexpμt+0tλ1s+λ2sdsπexpμt+0tλ1s+λ2sds. (5)

Integrating both sides yields

St^expμt^+0t^λ1s+λ2sds0t^πexpμt^+0t^λ1w+λ2wdwdt^+C, (6)

where C is the constant of integration. Hence,

St^S0expμt^+0t^λ1s+λ2sds+expμt^+0t^λ1s+λ2sds0t^πexpμt^+0t^λ1w+λ2wdwdt^>0. (7)

Hence, St^>0t^>0.

From the second equation in system (1), we obtain

dVdt1ελ1+1ελ2+μV. (8)

Hence,

Vt^V0expμt^+0t^1ελ1s+1ελ2sds>0. (9)

Similarly, it can be shown that

Iwt^Iw0expb+α+aw+μt^>0,IRt^IR0expαr+ar+μt^>0,Rt^R0expϑ+μt^>0. (10)

Therefore, all the solutions of system (1) with nonnegative initial conditions will remain nonnegative for all time t > 0.

3.1.2. Invariant Region

We show that the total population is bounded for all time t > 0. The analysis of system (1) will therefore be analyzed in a region Ω of biological interest. Thus, we have the following theorem on the region that system (1) is restricted to.

Theorem 2 . —

The feasible regionΩdefined by

Ω=St,Vt,IWt,IRt,RtR5+0NmaxN0,Πμ, (11)

with initial conditionsS(0) ≥ 0, V(0) ≥ 0, IW(0) ≥ 0, IR(0) ≥ 0, and  R(0) ≥ 0, is positively invariant and attracting with respect to system (1) for allt > 0.

Proof —

Summing up the equations in (1), we obtain that the total population satisfies the following differential equation:

dNtdt=πμNawIwarIR. (12)

In the absence of influenza infection, it follows that

dNtdtπμN. (13)

It can easily be seen that

NtΠμ+N0Πμexpμt. (14)

From (14), we observe that as t, N(t) → (Π/μ). So if N(0) ≤ (Π/μ), then limtN(t)=(Π/μ). On the other hand, if N(0) > (Π/μ), then N will decrease to (Π/μ) as t. This means that N(t) ≤ max{N(0), (Π/μ)}. Therefore, N(t) is bounded above. Subsequently, S(t), V(t), Iw(t), IR(t), and  R(t) are bounded above. Thus, in Ω, system (1) is well posed. Hence, it is sufficient to study the dynamics of the system in Ω.

3.2. Existence of Equilibrium Points

In the absence of influenza (Iw=IR=0), system (1) has a disease-free equilibrium, which is given by

E0=S0,V0,0,0,0=Πϕ+μ,ϕΠμϕ+μ,0,0,0. (15)

3.2.1. The Control Reproduction Number

The control reproduction number, Rc, is a key threshold that determines the behaviour of the system in the presence of vaccination. In order to analyze the stability of system (1), we obtain the threshold condition for the establishment of the disease. Thus, we employ next-generation matrix operator method as explained in [60]. The matrices of new infections and transition terms evaluated at the disease-free equilibrium are given by

F=Πβwϕ1ε+μμμ+ϕ00Πβr¯ϕ1ε+μμμ+ϕ,V=b+α+μ+aw0bμ+ar+αr. (16)

The dominant eigenvalue corresponding to the spectral radius ρ(FV−1) of the matrix FV−1 is the control reproduction number, which is given by

Rc=maxRcw,Rcr, (17)

where

Rcw=βwπμ+ϕ1εμϕ+μα+b+aw+μ,Rcr=βr¯πμ+1εϕμϕ+μαr+ar+μ. (18)

Rcw is a measure of the average number of secondary wild-type influenza infections caused by a single infected individual introduced into the model population. On the other hand, Rcr gives the average number of secondary resistant influenza infections caused by one infected individual introduced into the model population.

From Theorem 2 in [60], we have the following results.

Proposition 1 . —

The disease-free equilibrium is locally asymptotically stable whenever Rc is less than unity and unstable otherwise.

Proof —

The Jacobian matrix evaluated at E0 is obtained as

JE0=ϕμ0βwS0βr¯S0ϑϕμ1εβwV01εβr¯V0000βwS0+1εβwV0Q10000bβr¯S0+1εβr¯V0Q2000ααrϑμ, (19)

where Q1=α+b+aw+μ and Q2=αr+ar+μ.

For the DFE to be locally stable, the eigenvalues of J(E0) must have negative real parts.

The characteristic polynomial of J(E0) is given by

Pλ=λ+μλ+μ+ϑλ+μ+ϕμμ+ϕar+λ+μ+αrΠβr¯μεϕ+ϕμμ+ϕaw+α+b+λ+μΠβwμεϕ+ϕ. (20)

Clearly, the following eigenvalues with negative real parts can be obtained from the polynomial (20): λ1=−μ, λ2=−μϑ, and  λ3=−μϕ. Other roots can be obtained from the remaining part of the polynomial (20), which is given by

P1λ=μμ+ϕar+λ+μ+αrΠβr¯μεϕ+ϕμμ+ϕaw+α+b+λ+μΠβwμεϕ+ϕ. (21)

Hence, we obtain

λ4=μμ+ϕar+μ+αr+πβr¯μ+ϕ1εμμ+ϕ,λ4=Q21Rcr,λ5=μμ+ϕb+α+μ+aw+πβwμ+ϕ1εμμ+ϕ,λ5=Q11Rcw. (22)

From (22), if Rcr < 1, then λ4 < 0, and if Rcw < 1, then λ5 < 0.

We therefore conclude that the disease-free equilibrium E0 is locally asymptotically stable whenever Rc < 1. The biological implication of Proposition 1 is that if Rc < 1, influenza will be eliminated from the model population provided that the initial sizes of the subpopulations in various compartments of model (1) are in the basin of attraction of the influenza-free equilibrium.

3.2.2. Effective Reproduction Number

The effective reproduction number (Re(t)) is the actual average number of secondary cases per primary case at calendar time t (for t > 0) [61]. Re(t) shows time-dependent variation due to decline in susceptible individuals and the implementation of control measures. The effective reproduction number is therefore used to characterize transmissibility in a population that is not entirely susceptible. It is the basic reproduction number times the fraction of the population that is susceptible to infection at time t.

The basic reproduction number (R0) is the average number of secondary infections generated by a single infective individual in a totally susceptible population [60]. From model (1), the basic reproduction number is obtained as

R0=maxβwπμμ2α+b+aw+μ,βr¯πμμ2αr+ar+μ. (23)

Thus, the effective reproduction number Re(t) = fR0, where f is the fraction of population susceptible to infection at a time t.

3.3. Endemic Equilibria

The endemic equilibria of model (1)are the steady states where influenza may persist in the population. This happens when at least one of the infected classes of the model is nonempty. The rate of change in populations in each compartment is zero at equilibrium; hence, the right-hand side of (1) is set to zero as follows:

0=π+ϑRϕ+μ+λ1+λ2S,0=ϕS1ελ1+1ελ2+μV,0=λ1S+1ελ1Vb+μ+aw+αIw,0=λ2S+1ελ2V+bIwμ+αr+arIR,0=αIw+αrIRϑ+μR. (24)

Next, S, V, Iw, IR, and R are solved from (24) in terms of the two forces of infection, λ1 and λ2 to obtain

S=π+ϑRμ+ϕ+λ1+λ2,V=ϕπ+ϑRμ+ϕ+λ1+λ2μ1+ελ11+ελ2,Iw=π+ϑRλ1μ+ϕεϕ1+ελ11+ελ2Q1μ+ϕ+λ1+λ2μ1+ελ11+ελ2,IR=π+ϑRμ+ϕεϕ1+ελ11+ελ2bλ1+Q1λ2Q1Q2μ+ϕ+λ1+λ2μ1+ελ11+ελ2,R=πμ+ϕεϕ1+ελ11+ελ2αQ2λ1+αrbλ1+Q1λ2ϑαQ2+bαrλ1μ+ϕεϕ1+ελ1+λ2ελ2+Q4. (25)

where

Q1=α+b+aw+μ,Q2=αr+ar+μ,Q3=ϑ+μ,Q4=Q1ϑαrλ2μ+1+εϕ+1+ελ1+1+ελ2+Q2Q3μ+ϕ+λ1+λ2μ1+ελ1+λ2ελ2. (26)

Upon dividing and simplifying the two expressions for λ1 and λ2, we obtain the following polynomial:

pλ1,λ2=πQ3λ1μ+ϕεϕ1+ελ11+ελ2Q2βwλ2+βr¯bλ1+Q1λ2. (27)

Note that if λ1=0 in the equation obtained when polynomial (27) is set to zero, then clearly λ2=0. This gives the disease-free equilibrium previously obtained in (15). The solutions to the remaining part of the polynomial (27), described by (28), define the possible endemic states of system (1).

pλ1,λ2=μ+ϕεϕ1+ελ11+ελ2Q2βwλ2+βr¯bλ1+Q1λ2=0. (28)

The existence of the endemic equilibrium points for system (1) depends on the solutions of (28), and the roots of the equation must be real and positive to guarantee existence of the endemic equilibrium point(s). Due to mathematical complexity, we are not able to express explicitly the endemic steady states of system (1). We shall however represent the polynomial in (28) graphically as shown in Figure 5.

Figure 5.

Figure 5

Endemic equilibrium points of the two-strain influenza model.

From the surface plot in Figure 5, it can be observed that there exist endemic steady states for the two-strain influenza model. The steady states only exist for positive values of p(λ1, λ2). The endemic equilibria exist in the case where only the wild-type strain is present, the case where only the resistant strain exists or both strains coexist.

3.3.1. Existence of an Endemic State with Wild-Type Strain Only

There exists an endemic state when the wild-type strain persists and the resistant strain dies out. Solving (1) in terms of λ1 yields

S=π+ϑRμ+ϕ+λ1,V=ϕπ+ϑRμ+ϕ+λ1μ+λ1ελ1,Iw=π+Rλ1μϕ+εϕλ1+ελ1Q1μ+ϕ+λ1μ+λ1ελ1,R=απλ1μ+ϕεϕ1+εQ1Q3μ+ϕ+λ1μ1+ελ1+αϑλ1μ+1+εϕ+1+ελ1. (29)

Substituting Iw obtained in (29) into λ1 yields polynomial (30) given by

λ1Q1Q3μ+ϕ+λ1μ1+ελ1μ+ϕεϕ1+ελ1ϕQ3βw+αϑλ1. (30)

It is important to note that when λ1=0, a wild-type strain-free equilibrium is obtained which is given by

S0,V0,0,0=Πϕ+μ,ϕΠμϕ+μ,0,0. (31)

The remaining part of polynomial (30) can be expressed as

Pλ1=D2λ12+D1λ1+D0. (32)

where

D2=1εQ1Q3αϑ,D1=Q31+εμ+ϕεϕQ1+1+επβwαμ+ϕεϕϑ,D0=Q3μμ+ϕQ11Rcw. (33)

The roots of the quadratic equation obtained when the polynomial in (32) is set to zero can be obtained by the quadratic formula given by

λ1=D1±D124D2D02D2. (34)

Note that D0 > 0 if Rcw < 1, D0=0 if Rcw=1, and D0 < 0 if Rcw > 1. If D0 < 0, the discriminant Δ = D12 − 4D2D0 > 0 and (32) have a unique positive solution, and hence, the model system (1) has a unique wild-type influenza persistent equilibrium. If Rcw < 1, then D0 > 0, and by adding the conditions D1 < 0 and Δ > 0, two positive real equilibria are obtained. If Rcw=1, then D0=0, and there is a unique nonzero solution of (32) which is positive if and only if D1 < 0. The following theorem summarizes the existence of the wild-type influenza endemic equilibria.

Theorem 3 . —

The model system (1) has

  1. a unique endemic equilibrium if Rcw > 1

  2. two endemic equilibria if Rcw < 1, D1 < 0, and Δ > 0

  3. one positive equilibrium for Rcw=1 and D1 < 0

  4. no wild-type influenza endemic equilibrium otherwise

Epidemiologically, Theorem 3 item (ii) implies that bringing Rcw below unity does not suffice for the eradication of wild-type influenza since system (1) exhibits backward bifurcation when Rcw < 1. The existence of backward bifurcation indicates that in the neighbourhood of 1, for Rcw < 1, a stable wild-type influenza-free equilibrium coexists with a stable wild-type influenza persistent equilibrium. In order to eradicate the disease, the control reproduction Rcw should be decreased below the critical value Rcw. To obtain Rcw, the discriminant in (32) is set to zero and Rcw made the subject of the relation. This yields

Rcw=1D124μμ+ϕQ1Q3D2. (35)

It follows that backward bifurcation occurs for values of Rcw such that Rcw < Rcw < 1. This is illustrated by Figure 6.

Figure 6.

Figure 6

Force of infection, λ1, versus control reproduction number, Rcw.

3.3.2. Existence of Resistant Influenza Strain Only Endemic State

There exists an endemic state when the resistant strain persists and the wild-type strain dies out. Solving (1) in terms of λ2 and substituting IR into λ2 yields the following equation:

λ2Q2Q3μ+ϕ+λ2μ1+ελ2+μ+ϕεϕ1+ελ2ϕQ3βr¯+αrϑλ2=0. (36)

When λ2=0, resistant influenza-free equilibrium is obtained. The remaining part of polynomial (36) can be expressed as

Pλ2=A2λ22+A1λ2+A0, (37)

where

A2=1+εQ2Q3αrϑ,A1=αrϕϑε1+Q2Q3μ1ε+Q2Q3ϕ1ε+Q3βr¯πε1αrμϑ,A0=Q3μμ+ϕQ21Rcr. (38)

Using the procedure as in Section 3.3.1, it can be shown that the system exhibits a backward bifurcation when Rcr < 1. This is illustrated by Figure 7.

Figure 7.

Figure 7

Force of infection, λ2, versus control reproduction number, Rcr.

4. Sensitivity Analysis

In order to curb the spread of influenza in a given population, it is essential to know the relative importance of the different parameters responsible for its transmission and prevalence. Influenza transmission and endemicity are directly related to Rc. As in [62, 63], the normalized forward sensitivity analysis is used for this model. The normalized sensitivity index which measures the relative change in a parameter k, with respect to the reproduction number Rc is given by Pq=(k/Rc)(∂Rc/∂k), [64]. The sign of Pq determines the direction of changes, increasing (for positive Pq) and decreasing (for negative Pq) [65]. The sensitivity indices of the model reproduction number to the parameters in the model at the parameter values described in Table 2 are calculated. These indices reveal how crucial each parameter is to disease transmission and spread making it possible to discover parameters that have a high impact on Rc and should be targeted by intervention strategies. The calculated sensitivity indices of Rc are given in Table 3.

Table 3.

Sensitivity indices of Rcw and Rcr.

Parameter Sensitivity index
Sensitivity indices ofR cw
β w 0.99999
π 1
ϕ −0.2582418982
ε −2.064509968
α −0.6094452335
a w −0.0305027644
b −0.3599326204
μ −0.7418774828

Sensitivity indices ofR cr
β r 0.99999
π 1
b 0.02746556942
ϕ −0.2582418983
ε −2.064509968
α r −0.7724001063
a r −0.2271765018
μ −0.7421814939

Small variations in a highly sensitive parameter lead to large quantitative changes; hence, caution should be taken when handling such a parameter. A positive sensitivity index indicates that Rc is an increasing function of the corresponding parameter, and hence, an increase in the parameter while other factors are held constant leads to an increase in the reproduction number and could lead to disease spread [65]. On the other hand, a negative sensitivity index shows that an increase in the parameter while other factors are held constant leads to a decrease in the reproduction number, which could then lead to disease control. For instance, if the vaccination rate, ϕ, is increased by 10%, Rc would decrease by about 2.5%. Increasing the recruitment rate by 10% increases the Rc by 10%.

5. Numerical Simulation

5.1. Effects of Drug Resistance

For the parameter values in Table 2, as the drug resistance increases, the changes in the reproduction numbers can be observed as shown in Figure 8.

Figure 8.

Figure 8

Relationship between reproduction numbers and drug resistance.

In conformity with the expectation, increased drug resistance leads to an increase in Rcr. It can also be observed that Rcw decreases with increased drug resistance. The implication of increased drug resistance on infected population is discussed in the next section.

5.1.1. Effects of Drug Resistance on Infected Population

The rate of drug resistance is varied holding all the other parameter values constant. Figures 9 and 10 are obtained.

Figure 9.

Figure 9

Effect of drug resistance on IR class.

Figure 10.

Figure 10

Effect of drug resistance on Iw class.

It can be observed from Figure 9 that when there is no development of drug resistance (b=0), the number of individuals infected with resistant strain decreases to zero. An increase in the rate of drug resistance leads to an increase in the number of individuals infected with resistant strain.

Next, the effect of drug resistance on individuals infected with wild-type strain is investigated.

From Figure 10, it can be observed that an increase in the rate of drug resistance leads to a decrease in the number of individuals infected with wild-type strain. For instance, when b=1, the number of individuals infected with wild-type strain decrease to zero. This could be attributed to the mutation of the wild-type strain to resistant strain.

5.2. Effect of Vaccination on Reproduction Number and on Influenza Prevalence in the Model Population

Figures 11 and 12 show the population dynamics of the infected individuals in a case where there is no vaccination. The reproduction number of the resistant strain is obtained as 2.7762, while that of the wild-type strain is obtained as 3.0288.

Figure 11.

Figure 11

I R individuals with no vaccination.

Figure 12.

Figure 12

I w individuals with no vaccination.

Note that the reproduction number for the two cases is greater than one. It can be observed from Figures 11 and 12 that the resistant strain and the wild-type strain persist in the population.

Next, numerical simulation is done in the case where there is vaccination. Using the parameter values in Table 2, Figures 13 and 14 are obtained. The control reproduction number (17), Rcr, is obtained as 0.9059, and Rcw is obtained as 0.9883.

Figure 13.

Figure 13

I R individuals with vaccination.

Figure 14.

Figure 14

I w individuals with vaccination.

Note that the reproduction number in this case is less than one. Vaccination reduces the reproduction number. However, from Figures 13 and 14, it can be observed that both the resistant strain and the wild-type strain do not completely die out from the population despite the reproduction number being less than one. These findings are consistent with Figures 6 and 7 obtained in Sections 3.3.1 and 3.3.2, respectively. This shows that bringing the reproduction number below unity does not describe the necessary effort to curb the spread of influenza. Therefore, the intervention strategies should be carefully implemented to bring the reproduction number below the critical value. It can also be observed from Figures 1114 that the level of persistence of the resistant strain is higher than that of the wild-type strain.

5.3. Effect of Transmission Rates βw and βr on Infected Population

5.3.1. Case 1: Effect of βw on Iw Individuals

From Figure 15, it can be observed that the higher the transmission rate, the higher the number of infected individuals. The number of infected individuals drastically decreases to zero within a short period of time but then starts to increase again shortly after and the disease does not completely die out after that (this is when βw = 0.002 and 0.0015). When βw = 0.00095, it can be observed that the number of infected individuals declines to zero and the disease completely dies out. It should be noted that for this case, the Rcw = 0.9205 which is below the critical value Rcw = 0.9351.

Figure 15.

Figure 15

Effect of βw on individuals infected with wild-type strain.

5.3.2. Case 2: Effect of βr on IR Individuals

It is observed from Figure 16 that the higher the transmission rate, the higher the number of infected individuals. It is also interesting to note that when βr = 0, there still exist individuals infected with the resistant strain and the strain persists in the population. This shows that curbing the spread of the resistant strain is quite difficult. This could be due to the fact that the spread of the resistant strain is fuelled by two processes: transmission and mutation of the wild-type strain to resistant strain.

Figure 16.

Figure 16

Effect of βr on individuals infected with resistant strain.

6. Conclusion

To completely wipe out influenza from a population continues to prove difficult. This is because the virus evolves very rapidly and is able to change from one season to the other. This is extensively explained in [3, 7, 9]. Results from our model show that vaccination reduces the reproduction number, and hence, it could be used as a control strategy. However, caution should be taken because influenza can still persist in case there is backward bifurcation. Results also show that it is easier to curtail the spread of the wild-type strain especially in a given season than the resistant strain. This could be through social distancing and issuing travel bans to areas affected with the virus. For the resistant strain, social distancing could also be used as a control strategy in addition to reducing the mutation of the wild-type strain.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

References

  • 1.White M. C., Lowen A. C. Implications of segment mismatch for influenza a virus evolution. Journal of General Virology. 2017;99(1):3–16. doi: 10.1099/jgv.0.000989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Taubenberger J. K., Morens D. M. Influenza viruses: breaking all the rules. mBio. 2013;4(4) doi: 10.1128/mbio.00365-13.e00365-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.CDC. How the Flu Virus Can Change: Drift and Shift. Atlanta, GA, USA: CDC; 2017. https://www.cdc.gov/flu/about/viruses/change.htm. [Google Scholar]
  • 4.Smith G. J., Vijaykrishna D., Bahl J., et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza a epidemic. Nature. 2009;459(7250):p. 1122. doi: 10.1038/nature08182. [DOI] [PubMed] [Google Scholar]
  • 5.WHO. WHO/Europe—Influenza-Data and Statistics. Geneva, Switzerland: WHO; 2017. http://www.euro.who.int/en/health-topics/communicable-diseases/influenza/data-and-statistics. [Google Scholar]
  • 6.CDC. Clinical Signs and Symptoms of Influenza: Health Professionals–CDC. Atlanta, GA, USA: CDC; 2017. https://www.cdc.gov/flu/professionals/acip/clinical.htm. [Google Scholar]
  • 7.Moscona A. Neuraminidase inhibitors for influenza. New England Journal of Medicine. 2005;353(13):1363–1373. doi: 10.1056/nejmra050740. [DOI] [PubMed] [Google Scholar]
  • 8.CDC. Preventing the Flu: Good Health Habits Can Help Stop Germs–CDC. Atlanta, GA, USA: CDC; 2017. https://www.cdc.gov/flu/protect/habits.htm. [Google Scholar]
  • 9.Matheka D. M., Mokaya J., Maritim M. Overview of influenza virus infections in Kenya: past, present and future. Pan African medical journal. 2013;14 doi: 10.11604/pamj.2013.14.138.2612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Cheng K., Leung P. What happened in china during the 1918 influenza pandemic? International Journal of Infectious Diseases. 2007;11(4):360–364. doi: 10.1016/j.ijid.2006.07.009. [DOI] [PubMed] [Google Scholar]
  • 11.Goeyvaerts N., Willem L., Van Kerckhove K., et al. Estimating dynamic transmission model parameters for seasonal influenza by fitting to age and season-specific influenza-like illness incidence. Epidemics. 2015;13:1–9. doi: 10.1016/j.epidem.2015.04.002. [DOI] [PubMed] [Google Scholar]
  • 12.Saunders-Hastings P. R., Krewski D. Reviewing the history of pandemic influenza: understanding patterns of emergence and transmission. Pathogens. 2016;5(4):p. 66. doi: 10.3390/pathogens5040066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.CDC. Past Pandemics. Atlanta, GA, USA: CDC; 2017. https://www.cdc.gov/flu/pandemic-resources/basics/past-pandemics.html. [Google Scholar]
  • 14.WHO. WHO—Influenza. Geneva, Switzerland: WHO; 2017. http://www.who.int/mediacentre/factsheets/2003/fs211/en/ [Google Scholar]
  • 15.CDC. Seasonal Flu Death Estimate Increases Worldwide. Atlanta, GA, USA: CDC; 2017. https://www.cdc.gov/media/releases/2017/p1213-flu-death-estimate.html. [Google Scholar]
  • 16.Hope-Simpson R. The role of season in the epidemiology of influenza. Epidemiology & Infection. 1981;86(1):35–47. doi: 10.1017/s0022172400068728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Finkelman B. S., Viboud C., Koelle K., Ferrari M. J., Bharti N., Grenfell B. T. Global patterns in seasonal activity of influenza A/H3N2, A/H1N1, and B from 1997 to 2005: viral coexistence and latitudinal gradients. PLoS One. 2007;2(12) doi: 10.1371/journal.pone.0001296.e1296 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Shek L. P.-C., Lee B.-W. Epidemiology and seasonality of respiratory tract virus infections in the tropics. Paediatric Respiratory Reviews. 2003;4(2):105–111. doi: 10.1016/s1526-0542(03)00024-1. [DOI] [PubMed] [Google Scholar]
  • 19.Katz M. A., Schoub B. D., Heraud J. M., Breiman R. F., Njenga M. K., Widdowson M.-A. Influenza in Africa: uncovering the epidemiology of a long-overlooked disease. Journal of Infectious Diseases. 2012;206(1):S1–S4. doi: 10.1093/infdis/jis548. [DOI] [PubMed] [Google Scholar]
  • 20.WHO. Influenza. Geneva, Switzerland: WHO; 2017. http://www.who.int/influenza/gisrs_laboratory/updates/summaryreport_20171002/en/ [Google Scholar]
  • 21.WHO. Influenza. Geneva, Switzerland: WHO; 2018. http://www.who.int/influenza/gisrs_laboratory/updates/summaryreport/en/ [Google Scholar]
  • 22.RGA. Seasonal Influenza and Mortality. St. Louis, MO, USA: RGA; 2018. https://www.rgare.com/knowledge-center/articles/seasonal-influenza-and-mortality. [Google Scholar]
  • 23.Ku A., Chan L. The first case of H5N1 avian influenza infection in a human with complications of adult respiratory distress syndrome and Reye’s syndrome. Journal of Paediatrics and Child Health. 1999;35(2):207–209. doi: 10.1046/j.1440-1754.1999.t01-1-00329.x. [DOI] [PubMed] [Google Scholar]
  • 24.Hien T. T., Liem N. T., Dung N. T., et al. Avian influenza a (H5N1) in 10 patients in Vietnam. New England Journal of Medicine. 2004;350(12):1179–1188. doi: 10.1056/nejmoa040419. [DOI] [PubMed] [Google Scholar]
  • 25.Gao R., Cao B., Hu Y., et al. Human infection with a novel avian-origin influenza a (H7N9) virus. New England Journal of Medicine. 2013;368(20):1888–1897. doi: 10.1056/nejmoa1304459. [DOI] [PubMed] [Google Scholar]
  • 26.Mazel-Sanchez B., Boal-Carvalho I., Silva F., Dijkman R., Schmolke M. H5N1 influenza a virus PB1-F2 relieves HAX-1-mediated restriction of avian virus polymerase pa in human lung cells. Journal of Virology. 2018;92(11):p. e00425–18. doi: 10.1128/jvi.00425-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Hurtado T. R. Human influenza a (H5N1): a brief review and recommendations for travelers. Wilderness & Environmental Medicine. 2006;17(4):276–281. doi: 10.1580/06-weme-ra-007r.1. [DOI] [PubMed] [Google Scholar]
  • 28.Li F., Choi B., Sly T., Pak A. Finding the real case-fatality rate of H5N1 avian influenza. Journal of Epidemiology & Community Health. 2008;62(6):555–559. doi: 10.1136/jech.2007.064030. [DOI] [PubMed] [Google Scholar]
  • 29.WHO. Influenza at the Human-Animal Interface. Geneva, Switzerland: WHO; 2018. http://www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface_25_01_2018_FINAL.pdf. [Google Scholar]
  • 30.Chen H., Yuan H., Gao R., et al. Clinical and epidemiological characteristics of a fatal case of avian influenza a h10n8 virus infection: a descriptive study. The Lancet. 2014;383(9918):714–721. doi: 10.1016/s0140-6736(14)60111-2. [DOI] [PubMed] [Google Scholar]
  • 31.Zhang Z., Li R., Jiang L., et al. The complexity of human infected AIV H5N6 isolated from china. BMC Infectious Diseases. 2016;16(1):p. 600. doi: 10.1186/s12879-016-1932-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Huang Y., Li X., Zhang H., et al. Human infection with an avian influenza a (H9N2) virus in the middle region of china. Journal of Medical Virology. 2015;87(10):1641–1648. doi: 10.1002/jmv.24231. [DOI] [PubMed] [Google Scholar]
  • 33.Yuan J., Zhang L., Kan X., et al. Origin and molecular characteristics of a novel 2013 avian influenza a (H6N1) virus causing human infection in Taiwan. Clinical Infectious Diseases. 2013;57(9):1367–1368. doi: 10.1093/cid/cit479. [DOI] [PubMed] [Google Scholar]
  • 34.Alexander M. E., Bowman C., Moghadas S. M., Summers R., Gumel A. B., Sahai B. M. A vaccination model for transmission dynamics of influenza. SIAM Journal on Applied Dynamical Systems. 2004;3(4):503–524. doi: 10.1137/030600370. [DOI] [Google Scholar]
  • 35.Guo D., Li K. C., Peters T. R., Snively B. M., Poehling K. A., Zhou X. Multi-scale modeling for the transmission of influenza and the evaluation of interventions toward it. Scientific Reports. 2015;5(1) doi: 10.1038/srep08980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Srivastav A. K., Ghosh M. Analysis of a simple influenza a (H1N1) model with optimal control. World Journal of Modelling and Simulation. 2016;12(4):307–319. [Google Scholar]
  • 37.Mikolajczyk R., Krumkamp R., Bornemann R., Ahmad A., Schwehm M., Duerr H. Influenza–insights from mathematical modelling. Deutsches Arzteblatt International. 2009;106(47):777–782. doi: 10.3238/arztebl.2009.0777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Larson E. W., Dominik J. W., Rowberg A. H., Higbee G. A. Influenza virus population dynamics in the respiratory tract of experimentally infected mice. Infection and Immunity. 1976;13(2):438–447. doi: 10.1128/iai.13.2.438-447.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Imran M., Malik T., Ansari A. R., Khan A. Mathematical analysis of swine influenza epidemic model with optimal control. Japan Journal of Industrial and Applied Mathematics. 2016;33(1):269–296. doi: 10.1007/s13160-016-0210-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Lee S., Chowell G., Castillo-Chávez C. Optimal control for pandemic influenza: the role of limited antiviral treatment and isolation. Journal of Theoretical Biology. 2010;265(2):136–150. doi: 10.1016/j.jtbi.2010.04.003. [DOI] [PubMed] [Google Scholar]
  • 41.Prosper O., Saucedo O., Thompson D., Torres-Garcia G., Wang X., Castillo-Chavez C. Modeling control strategies for concurrent epidemics of seasonal and pandemic H1N1 influenza. Mathematical Biosciences and Engineering. 2011;8(1):141–170. doi: 10.3934/mbe.2011.8.141. [DOI] [PubMed] [Google Scholar]
  • 42.Woolhouse M., Farrar J. Policy: an intergovernmental panel on antimicrobial resistance. Nature. 2014;509(7502):555–557. doi: 10.1038/509555a. [DOI] [PubMed] [Google Scholar]
  • 43.van der Vries E., Schutten M., Fraaij P., Boucher C., Osterhaus A. Influenza virus resistance to antiviral therapy. Advances in Pharmacology. 2013;67:217–246. doi: 10.1016/B978-0-12-405880-4.00006-8. [DOI] [PubMed] [Google Scholar]
  • 44.Li T., Chan M. C., Lee N. Clinical implications of antiviral resistance in influenza. Viruses. 2015;7(9):4929–4944. doi: 10.3390/v7092850. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.CDC. About Antimicrobial Resistance—Antibiotic/Antimicrobial Resistance. Atlanta, GA, USA: CDC; 2017. https://www.cdc.gov/drugresistance/about.html. [Google Scholar]
  • 46.Hayes J. D., Wolf C. R. Molecular mechanisms of drug resistance. Biochemical Journal. 1990;272(2):p. 281. doi: 10.1042/bj2720281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Blower S., Aschenbach A., Gershengorn H., Kahn J. Predicting the unpredictable: transmission of drug-resistant HIV. Nature Medicine. 2001;7(9):1016–1020. doi: 10.1038/nm0901-1016. [DOI] [PubMed] [Google Scholar]
  • 48.Blower S., Volberding P. What can modeling tell us about the threat of antiviral drug resistance? Current Opinion in Infectious Diseases. 2002;15(6):609–614. doi: 10.1097/00001432-200212000-00009. [DOI] [PubMed] [Google Scholar]
  • 49.Ison M. G., Gubareva L. V., Atmar R. L., Treanor J., Hayden F. G. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. Journal of Infectious Diseases. 2006;193(6):760–764. doi: 10.1086/500465. [DOI] [PubMed] [Google Scholar]
  • 50.Kamali A., Holodniy M. Influenza treatment and prophylaxis with neuraminidase inhibitors: a review. Infection and Drug Resistance. 2013;6:p. 187. doi: 10.2147/IDR.S36601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.CDC. Influenza Antiviral Drug Resistance. Atlanta, GA, USA: CDC; 2017. https://www.cdc.gov/flu/about/qa/antiviralresistance.htm. [Google Scholar]
  • 52.Hayden F. G., de Jong M. D. Emerging influenza antiviral resistance threats. Journal of Infectious Diseases. 2011;203(1):6–10. doi: 10.1093/infdis/jiq012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Lipsitch M., Cohen T., Murray M., Levin B. R. Antiviral resistance and the control of pandemic influenza. PLoS Medicine. 2007;4(1):p. e15. doi: 10.1371/journal.pmed.0040015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Jnawali K., Morsky B., Poore K., Bauch C. T. Emergence and spread of drug resistant influenza: a two-population game theoretical model. Infectious Disease Modelling. 2016;1(1):40–51. doi: 10.1016/j.idm.2016.07.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.McCaw J. M., Wood J. G., McCaw C. T., McVernon J. Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs. PLoS One. 2008;3(6) doi: 10.1371/journal.pone.0002362.e2362 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Ferguson N. M., Mallett S., Jackson H., Roberts N., Ward P. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. Journal of Antimicrobial Chemotherapy. 2003;51(4):977–990. doi: 10.1093/jac/dkg136. [DOI] [PubMed] [Google Scholar]
  • 57.Stilianakis N. I., Perelson A. S., Hayden F. G. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. Journal of Infectious Diseases. 1998;177(4):863–873. doi: 10.1086/515246. [DOI] [PubMed] [Google Scholar]
  • 58.ISG. Vaccine Efficacy and Effectiveness. Melbourne, VIC, Australia: Influenza Specialist Group; 2017. http://www.isg.org.au/index.php/vaccination/vaccine-efficacy-and-effectiveness/ [Google Scholar]
  • 59.CDC. Flu Vaccine Coverage Remains Low This Year. Atlanta, GA, USA: Centers for Disease Control and Prevention; 2017. https://www.cdc.gov/media/releases/2016/p1207-flu-vaccine-coverage.html. [Google Scholar]
  • 60.Van den Driessche P., Watmough J. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Mathematical Biosciences. 2002;180(1):29–48. doi: 10.1016/s0025-5564(02)00108-6. [DOI] [PubMed] [Google Scholar]
  • 61.Nishiura H., Chowell G. Mathematical and Statistical Estimation Approaches in Epidemiology. Berlin, Germany: Springer; 2009. The effective reproduction number as a prelude to statistical estimation of time-dependent epidemic trends; pp. 103–121. [Google Scholar]
  • 62.Rodrigues H. S., Monteiro M. T. T., Torres D. F. M. Sensitivity analysis in a dengue epidemiological model. Conference Papers in Science. 2013;2013:7. doi: 10.1155/2013/721406.721406 [DOI] [Google Scholar]
  • 63.Chitnis N., Hyman J. M., Manore C. A. Modelling vertical transmission in vector-borne diseases with applications to rift valley fever. Journal of Biological Dynamics. 2013;7(1):11–40. doi: 10.1080/17513758.2012.733427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Hategekimana F., Saha S., Chaturvedi A. Dynamics of amoebiasis transmission: stability and sensitivity analysis. Mathematics. 2017;5(4):p. 58. doi: 10.3390/math5040058. [DOI] [Google Scholar]
  • 65.Chowell G., Hyman J. M. Mathematical and Statistical Modeling for Emerging and Re-emerging Infectious Diseases. Berlin, Germany: Springer; 2016. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data used to support the findings of this study are included within the article.


Articles from Computational and Mathematical Methods in Medicine are provided here courtesy of Wiley

RESOURCES